Amgen Inc. vs Broadcom Inc.: Strategic Comparison

This in-depth comparison examines Amgen Inc. and Broadcom Inc. across revenue, market value, business model, competitive positioning, and long-term growth strategy. Whether you are researching Amgen Inc. on its own, evaluating Broadcom Inc., or weighing the two companies side by side, the breakdown below highlights where each company leads and where the gap between Amgen Inc. and Broadcom Inc. is widest.

On the headline numbers, Amgen Inc. reports annual revenue of $36.8B against $63.9B for Broadcom Inc., while their respective market capitalizations stand at $153.0B and $800.0B. Amgen Inc. is headquartered in United States and Broadcom Inc. operates from United States, and those different home markets shape how each company competes.

Amgen Inc.: A Japanese brewery kept Amgen alive. The upfront payment kept Amgen's laboratory lights on. Five years later, EPO became the first blockbuster drug in biotechnology history. The Kirin deal was not charity; it was a calculated exchange of geographic rights for survival capital. Without it, there might be no Amgen. The FTC sued to block the deal, arguing that Amgen could use its portfolio rebate structures to foreclose competing drugs from formularies. The companies won in court and closed the transaction. The companies won. The acquisition closed. It was the most expensive biotech deal of the year and among the largest in a decade, financed primarily with debt that raised Amgen's leverage ratio significantly. Thousand Oaks, California, 1980. In 1983, scientist Fu-Kuen Lin cloned the gene for erythropoietin, the hormone that signals bone marrow to produce red blood cells. Chemotherapy destroys bone marrow's ability to produce those cells, leaving cancer patients severely anemic and requiring frequent blood transfusions. A synthetic EPO could eliminate the need for transfusions. The FDA approved Epogen in 1989.

Broadcom Inc.: Broadcom combines a long operating history with a current strategy shaped by FY2025 financial results, leadership priorities, and competitive pressure.

Amgen Inc. and Broadcom Inc. pursue distinct approaches to generating revenue, and understanding how each company operates is the foundation of any fair comparison between Amgen Inc. and Broadcom Inc..

Amgen Inc. business model: This segment has lower margins than branded biologics but provides volume growth and demonstrates Amgen's commitment to lower-cost medicine access — a narrative that carries important political value during a period of intense congressional scrutiny of drug pricing. The problem is, Amgen's operating margins have typically run between 30% and 35% on a GAAP basis and higher on an adjusted basis, reflecting both the pricing power of its branded biologics and decades of operational refinement. Amgen's financial profile in fiscal year 2024 reflected both the far-reaching impact of the Horizon Therapeutics acquisition and the ongoing pressure from patent expirations and pricing pattern. Ten drugs were subject to the first round of negotiations for 2026 pricing, and Enbrel was among the drugs selected for the second cycle of negotiations targeting 2027. It added Tepezza for thyroid eye disease and Krystexxa for chronic refractory gout — rare disease assets with high per-patient pricing and limited competition.

Broadcom Inc. business model: Broadcom makes money through custom AI accelerators, ethernet switching silicon, wireless components, storage connectivity, VMware infrastructure software, and enterprise security software. Its model depends on disciplined capital allocation, durable customer or channel relationships, and execution inside markets where scale and trust matter.

The durability of a company's moat often decides long-term winners. Here is how the competitive advantages of Amgen Inc. stack up against those of Broadcom Inc..

Amgen Inc. competitive advantage: Before the first human clinical trial ever tested a biotech-derived protein drug, a small group of venture-backed scientists in a repurposed building in Newbury Park, California, were betting that living cells could be engineered to manufacture medicines at industrial scale — a concept so novel in 1980 that most of Wall Street barely had a vocabulary for it. What makes Amgen genuinely unusual among its peers is the combination of scientific credibility, manufacturing scale, and financial discipline it has maintained over four decades. That singular achievement — turning living cells into life-saving medicines at global scale — is the defining fact of Amgen's half-century existence. Amgen's business model is built on one of the most capital-intensive and intellectually demanding processes in American enterprise: translating fundamental biological discoveries into regulated, manufactured medicines that can be sold at scale. Amgen's manufacturing organization is among the most sophisticated in the biopharma industry, running validated large-scale biologic production at facilities in Thousand Oaks, California; West Greenwich, Rhode Island; Juncos, Puerto Rico; Breda, Netherlands; and Singapore. While Amgen's MariTide program represents a genuine opportunity, it enters a market where Eli Lilly's Zepbound (tirzepatide) and Novo Nordisk's Wegovy (semaglutide) have already established billion-dollar revenue bases and massive manufacturing advantages. Amgen's most durable competitive advantage is its manufacturing expertise in large-molecule biologics. Financially, Amgen's scale generates operating use that smaller biotech firms cannot match. EPO had been identified and partially characterized in previous research, but no one had successfully cloned the human EPO gene and produced recombinant EPO protein at meaningful scale. The recombinant DNA tools available in 1980 were primitive by modern standards, but they were sufficient to do something that had never been done: clone human genes, insert them into bacterial or mammalian cell cultures, and produce therapeutic proteins at commercial scale.

Broadcom Inc. competitive advantage: The ethernet switching chips that route data across the world's hyperscale data centers, the Wi-Fi and Bluetooth radios embedded in virtually every iPhone Apple has shipped in over a decade, the storage controllers managing enterprise disk arrays, and the broadband gateway chips terminating cable modems in tens of millions of American homes — all of these are Broadcom products. The company's approach to semiconductor design is explicitly not to compete across all categories — it does not make CPUs, consumer GPUs for gaming, or memory chips — but rather to identify connectivity, networking, and signal processing niches where the economics favor long design cycles, high switching costs, and customer relationships that span decades rather than product generations. Broadcom's Tomahawk and Trident series of ethernet switching ASICs are the industry standard for hyperscale data center switching fabrics. The company holds an estimated 60 to 70 percent share of the merchant silicon market for high-end data center switching, a position reinforced by an enormous software ecosystem and years of co-engineering with network operating system vendors. This guidance, when it was articulated in late 2024, was one of the most bullish data points from any technology company regarding the scale of the AI infrastructure investment cycle. Customers who invest years of software integration work atop Broadcom silicon have enormous switching costs. The industry debate between InfiniBand (favored by Nvidia for training clusters) and ethernet (where Broadcom leads) plays out every time a hyperscaler designs a new AI data center. IBM's Red Hat OpenShift and the broader open-source Kubernetes ecosystem represent a longer-term architectural alternative — not a near-term VMware replacement for most enterprises, but a destination toward which application modernization efforts are directionally pointed. The Apple relationship provides Broadcom with guaranteed volume scale that makes its Wi-Fi business economically distinctive, but any disruption to that relationship would erode the cost position that makes Broadcom competitive in the broader merchant wireless market. Across these battlegrounds, what distinguishes Broadcom is not that it is winning every fight — in some areas, it is conceding markets it cannot defend profitably — but that it has systematically concentrated its resources in segments where switching costs are highest, customer relationships are deepest, and technological leads, once established, are durable. This curatorial approach to competition, unusual for a company of Broadcom's scale, is the strategic signature of the Hock Tan era and the clearest explanation for how a company that does not build the flashiest chips or write the most innovative software has become one of the most valuable technology companies on earth. For partners in the VMware ecosystem — the thousands of value-added resellers, managed service providers, and system integrators who had built businesses around VMware's channel program — Broadcom's simplification of the partner program and reduction of channel incentives created genuine business disruption. Finally, Broadcom faces the challenge of integration complexity at scale. Broadcom's competitive advantages are grounded in structural realities of its end markets rather than temporary technological leads, and understanding why the company wins consistently requires looking beyond product specifications to the economic architecture of customer relationships. The most powerful advantage is switching cost density — a concept that describes not merely the cost of changing a software contract but the cascading technical, operational, and financial cost of replacing a technology that is embedded across an organization's entire infrastructure. The same logic applies on the semiconductor side: the hardware and software ecosystem built atop a Broadcom Tomahawk switching ASIC — including the NOS software, management tools, and automation frameworks — makes displacing the silicon a multi-year engineering project. The company's custom AI accelerator program works so deeply with hyperscaler customers' internal teams that the resulting chips are, in many ways, co-owned intellectual achievements. Scale in manufacturing and design is a third pillar. Finally, Broadcom's financial model itself is a competitive advantage. Management has indicated that additional hyperscalers are evaluating custom ASIC programs, and winning one or two additional programs would materially expand the serviceable addressable market. The networking adjacency is equally significant: as AI clusters scale from thousands to hundreds of thousands of interconnected chips, the demand for high-bandwidth, low-latency ethernet switching — precisely Broadcom's core competency — scales proportionally.

Future prospects matter as much as current results. The growth strategies below explain how Amgen Inc. and Broadcom Inc. each plan to expand from here.

Amgen Inc. growth strategy: But those same drugs carry price tags that have triggered congressional hearings, federal investigations, and public outrage. Amgen generates revenue through four primary mechanisms: branded biologic product sales in the United States, international product sales in Europe and other markets, licensing and royalty income from partnerships, and a rapidly expanding biosimilars portfolio. Key pipeline assets include MariTide (maridebart cafraglutide), an investigational obesity and diabetes drug that targets both GLP-1 receptor agonism and GIP receptor antagonism — a mechanism that could position Amgen to compete directly with Eli Lilly's tirzepatide and Novo Nordisk's semaglutide in the exploding weight loss drug market. The company has also advanced AMG 133 through Phase 2 trials with weight loss data that attracted significant investor attention in 2024 and 2025. The capital investment required to build and validate these facilities — routinely running into hundreds of millions or billions of dollars per site — creates a structural barrier that reinforces Amgen's competitive position. The company has invested in next-generation multiproduct manufacturing facilities that can be adapted to different biologic drug types with shorter reconfiguration times, improving capital efficiency. Capital allocation historically favored a combination of R&D reinvestment, dividend payments (the quarterly dividend reached $2.25 per share in 2024, yielding approximately 3%), and share repurchases. While the United States accounted for approximately 75% of product revenues in 2024, the company has been growing its ex-U.S. Presence, particularly in Europe where biosimilars face more receptive regulatory and market environments than in the U.S. Amgen's European commercial infrastructure, bolstered by its 2013 acquisition of deCODE Genetics in Iceland and longstanding partnerships across major EU markets, provides both revenue diversification and access to genomic research populations that inform drug discovery. Amgen Inc. was established at the dawn of the biotechnology era and has grown to become the archetype of what a successful independent biotech company can achieve. The company is organized into research and development divisions focused on oncology, cardiovascular and metabolic diseases, inflammation, bone health, rare diseases, and neuroscience. Amgen's competitive posture has evolved from a largely defensive stance in the early 2010s — when it was focused primarily on defending Enbrel and Neulasta from biosimilar competition — toward a more aggressive offensive strategy combining pipeline development, strategic acquisitions, and biosimilar market entry. The question of how much revenue Amgen can sustain through the mid-2020s patent cliff cycle while simultaneously growing new franchises defines the company's near-term financial trajectory. Amgen's growth strategy rests on four interdependent pillars that CEO Robert Bradway has consistently articulated to investors since 2020. Tepezza has significant underpenetrated market opportunity — the vast majority of thyroid eye disease patients remain undertreated despite Tepezza's strong clinical evidence — and Amgen has invested heavily in patient identification programs, specialist education, and payer coverage expansion since the acquisition closed. The third pillar is building the biosimilars business into a durable revenue contributor. Amgen has committed to launching biosimilar versions of multiple high-revenue biologics as they lose exclusivity through 2030, using its manufacturing capabilities to achieve cost structures that enable profitable competition at biosimilar price points. The fourth pillar is disciplined financial management — specifically debt reduction from the Horizon acquisition while preserving R&D investment and the dividend. Management has targeted returning to investment-grade credit metrics by 2027, which would restore full capital allocation flexibility including potential smaller bolt-on acquisitions in therapeutic categories where Amgen wants to build pipeline depth. The geographic growth opportunity in emerging markets, particularly China and Japan, where Amgen is building direct commercial presence, represents a longer-term revenue diversification vector. Amgen is attempting to offset this through volume growth in Repatha, Otezla, Tepezza, and biosimilars, while simultaneously advancing pipeline assets in oncology including tarlatamab (AMG 757), a bispecific T-cell engager targeting DLL3 for small cell lung cancer that received FDA accelerated approval in May 2024. Tarlatamab's launch performance will be an important indicator of Amgen's ability to build new oncology franchises beyond its historical reliance on supportive care drugs. Bowes, a partner at the venture firm U.S. Venture Partners, conceived the idea of building a biotech company from the ground up with experienced professional management at its helm rather than waiting for academics to evolve into businesspeople. Rathmann was not a molecular biologist, but he was a scientist with deep industry experience and an intuitive understanding of how to build research organizations. The company's initial scientific strategy was deliberately broad: it would pursue multiple research directions in protein biology simultaneously, betting that some would eventually yield commercial products without pre-committing to any single therapeutic hypothesis. Amgen moved its operations to a leased building in Newbury Park, California (later incorporated into Thousand Oaks), hiring scientists from Caltech, UCLA, and major pharmaceutical companies. This partnership, unconventional in the extreme — a biotechnology company licensing its core technology to a brewery — demonstrated the creative financial pragmatism that would characterize Amgen's management style for decades. The dual-product base gave the company the financial stability to invest in a research pipeline that would take two more decades to produce its next generation of commercially significant medicines.

Broadcom Inc. growth strategy: Broadcom combines high-share semiconductor franchises with infrastructure software, then applies disciplined product focus, cost control, and cash-return policies.

A closer look at the financial trajectory of Amgen Inc. and Broadcom Inc. rounds out the comparison.

Amgen Inc.: Amgen reported FY2025 total revenues of $36.8 billion, up 10% year over year, and GAAP net income of $7.7 billion. Product sales grew on volume, with eighteen products reaching record annual sales and fourteen exceeding $1 billion. The Horizon acquisition continued to reshape the portfolio, while amortization, impairment charges, pricing pressure, and R&D investment kept GAAP margins below the cleaner non-GAAP picture.

Broadcom Inc.: Broadcom reported $63.9B in FY2025 revenue and $23.1B in net income/profit attributable to the company or shareholders. In fiscal 2025 Broadcom reported $63.887B in revenue, $23.126B in net income, $25.484B in operating income, and rapid AI semiconductor growth.